Two Sigma Investments LP Reduces Position in MiMedx Group, Inc. (NASDAQ:MDXG)

Two Sigma Investments LP reduced its position in shares of MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 18.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 395,907 shares of the company's stock after selling 92,228 shares during the quarter. Two Sigma Investments LP owned 0.27% of MiMedx Group worth $3,809,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of MDXG. IMG Wealth Management Inc. purchased a new stake in MiMedx Group during the fourth quarter valued at approximately $28,000. Van ECK Associates Corp bought a new position in MiMedx Group during the fourth quarter valued at $40,000. Tower Research Capital LLC TRC lifted its position in MiMedx Group by 77.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company's stock valued at $63,000 after purchasing an additional 2,837 shares during the last quarter. AlphaQuest LLC bought a new position in MiMedx Group during the fourth quarter valued at $88,000. Finally, Savant Capital LLC bought a new stake in shares of MiMedx Group in the 4th quarter worth about $100,000. 79.15% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently issued reports on MDXG. Cantor Fitzgerald restated an "overweight" rating and issued a $13.00 target price on shares of MiMedx Group in a report on Thursday, February 27th. Wall Street Zen downgraded shares of MiMedx Group from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 9th.

MiMedx Group Stock Down 1.2%

Shares of MiMedx Group stock traded down $0.08 on Friday, reaching $6.47. The stock had a trading volume of 571,892 shares, compared to its average volume of 690,770. The company has a 50 day moving average price of $6.94 and a 200 day moving average price of $8.14. The stock has a market capitalization of $955.63 million, a P/E ratio of 11.76 and a beta of 1.85. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. MiMedx Group, Inc. has a 1 year low of $5.47 and a 1 year high of $10.14.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last released its earnings results on Wednesday, April 30th. The company reported $0.06 EPS for the quarter, hitting analysts' consensus estimates of $0.06. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. The company had revenue of $88.21 million during the quarter, compared to analysts' expectations of $86.32 million. As a group, equities research analysts forecast that MiMedx Group, Inc. will post 0.3 EPS for the current year.

Insider Buying and Selling at MiMedx Group

In other news, insider Kimberly Maersk-Moller sold 4,106 shares of MiMedx Group stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $7.89, for a total transaction of $32,396.34. Following the completion of the transaction, the insider now directly owns 310,836 shares of the company's stock, valued at $2,452,496.04. The trade was a 1.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Joseph H. Capper bought 200,000 shares of the business's stock in a transaction dated Friday, May 2nd. The shares were purchased at an average cost of $6.34 per share, with a total value of $1,268,000.00. Following the completion of the acquisition, the chief executive officer now owns 529,530 shares in the company, valued at approximately $3,357,220.20. This represents a 60.69% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 141,907 shares of company stock worth $1,112,580. Company insiders own 1.70% of the company's stock.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.